COAG (COAG) Stock Price & Analysis
COAG (COAG) rose 5.68% to USD 27 as of June 10, 2026 at 10:00 UTC, according to Nexqual real-time market data.
COAG last closed at USD 25.55; the session ranged USD 25.5–27.61 on volume of 181,820 shares. Market capitalization is $1.26B, with a 52-week range of USD 23–36.61 (NMS). Source: Nexqual, June 10, 2026 at 10:00 UTC.
Key Statistics (as of June 10, 2026 at 10:00 UTC)
| Price | USD 27 |
|---|---|
| Change | ▲ 5.68% (up) |
| Previous Close | USD 25.55 |
| Open | USD 25.69 |
| Day Range | USD 25.5 – 27.61 |
| 52-Week Range | USD 23 – 36.61 |
| Volume | 181,820 shares |
| Market Cap | $1.26B |
| Exchange | NMS |
Technical Analysis (COAG)
Nexqual's technical model rates COAG "SELL" based on 0 bullish and 3 bearish signals across 26 daily candles, as of June 10, 2026 at 10:00 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 33.68 (neutral) |
| MACD | -0.34 (negative) |
Analyst Ratings (COAG)
Wall Street analysts rate COAG "Strong Buy" based on 4 analysts, with a mean price target of USD 41.75 (range USD 36–50), per Nexqual as of June 10, 2026 at 10:00 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 41.75 |
| High Target | USD 50 |
| Low Target | USD 36 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (COAG)
| Next Earnings Date | 2026-08-14 |
|---|---|
| EPS Estimate | USD -0.88 |
| Revenue Estimate | $0 |
Source: Nexqual, June 10, 2026 at 10:00 UTC.
Financials & Fundamentals (COAG)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -46.99% |
| Current Ratio | 18.03 |
| Free Cash Flow | $-39.59M |
Source: Nexqual, June 10, 2026 at 10:00 UTC.
Financial Health Score (COAG)
Nexqual rates COAG's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 10:00 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — No data |
| Cash Flow | Weak — Operating cash flow -$61M |
| Efficiency | Critical — ROE -47%, ROA -30.1% |
Ownership (COAG)
| Insider Ownership | +10.78% |
|---|---|
| Institutional Ownership | +59.90% |
| Shares Outstanding | 46.71M |
| Float | 456,133 |
Source: Nexqual, June 10, 2026 at 10:00 UTC.
Leadership (COAG)
COAG is led by Benny Sorensen (age 51), President, CEO & Director, per Nexqual as of June 10, 2026 at 10:00 UTC.
| President, CEO & Director | Benny Sorensen (age 51) |
|---|---|
| CFO & GM | Mads Nikolaj Behrndt-Eriksen M.Sc. (age 42) |
| Chief Operating Officer | Ananthram Sreenivasa Murthy M.Sc. (age 47) |
| Senior Vice President of CMC & Manufacturing | Cecile Bonvoisin M.Sc. |
| Senior Vice President of Development Operations | Tara O'Meara |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SPTX | Seaport Therapeutics, Inc. | USD 17.66 | ▲ 7.42% |
| AVLN | Avalyn Pharma Inc. | USD 28.67 | ▲ 5.95% |
| KLRA | Kailera Therapeutics, Inc. | USD 19.64 | ▲ 1.39% |
| ODTX | Odyssey Therapeutics, Inc. | USD 17.09 | ▲ 4.02% |
| EIKN | Eikon Therapeutics, Inc. | USD 8.77 | ▼ 2.12% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 10:00 UTC. This page is informational and not investment advice.